Zydus Cadila gets USFDA nod to market edema tablets
New Delhi: Zydus Cadila said it has received final approval from the US health regulator to market Bumetanide tablets used for the treatment of edema caused by conditions such as heart failure, among others.
The approval from the United States Food and Drug Administration (USFDA) is to market Bumetanide tablets USP in the strengths of 0.5 mg, 1 mg, and 2 mg, Zydus Cadila said in a statement.
The tablets will be manufactured in the group's manufacturing facility at Baddi, it added.
The tablets are "used to treat edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome", the company said.
The group now has more than 185 approvals and has so far filed over 320 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd